Press coverage about Alkermes PLC (NASDAQ:ALKS) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Alkermes PLC earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave headlines about the company an impact score of 46.2326021151381 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- Healthcare Stock in Buy Zone: Alkermes plc (ALKS) – Street Observer (press release) (streetobserver.com)
- Head to Head Survey: Alkermes PLC (ALKS) and The Competition (americanbankingnews.com)
- Stocks Trending Alert: Alkermes plc, (NASDAQ:ALKS), Allied Motion … – Stocks In The News (press release) (tradingnewsnow.com)
- Alkermes plc (ALKS) stock plunged -12.21% during recent three months – Street Observer (press release) (streetobserver.com)
- Alkermes plc (ALKS) moves -17.57% away from 52-Week High … – Voice Of Analysts (analystsbuzz.com)
A number of research firms have commented on ALKS. J P Morgan Chase & Co set a $78.00 price objective on shares of Alkermes PLC and gave the company a “buy” rating in a research note on Saturday, July 1st. BidaskClub downgraded shares of Alkermes PLC from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 9th. ValuEngine downgraded shares of Alkermes PLC from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Jefferies Group LLC set a $69.00 price objective on shares of Alkermes PLC and gave the company a “buy” rating in a research note on Friday, August 25th. Finally, Zacks Investment Research upgraded shares of Alkermes PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. One research analyst has rated the stock with a sell rating, six have given a hold rating and four have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $64.13.
Alkermes PLC (NASDAQ ALKS) opened at 51.56 on Thursday. The company’s market capitalization is $7.92 billion. Alkermes PLC has a 52-week low of $41.93 and a 52-week high of $63.40. The stock has a 50 day moving average of $51.06 and a 200-day moving average of $55.67.
Alkermes PLC (NASDAQ:ALKS) last posted its quarterly earnings results on Thursday, July 27th. The company reported $0.01 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.01) by $0.02. Alkermes PLC had a negative net margin of 24.33% and a negative return on equity of 9.12%. The firm had revenue of $218.80 million for the quarter, compared to the consensus estimate of $216.54 million. During the same quarter in the previous year, the company earned ($0.01) earnings per share. The business’s revenue was up 12.1% compared to the same quarter last year. On average, equities analysts forecast that Alkermes PLC will post ($0.04) earnings per share for the current year.
In other Alkermes PLC news, Director Paul J. Mitchell sold 1,500 shares of Alkermes PLC stock in a transaction on Friday, September 1st. The shares were sold at an average price of $50.77, for a total transaction of $76,155.00. Following the sale, the director now owns 9,500 shares in the company, valued at $482,315. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Kathryn L. Biberstein sold 13,566 shares of Alkermes PLC stock in a transaction on Monday, September 11th. The stock was sold at an average price of $51.29, for a total transaction of $695,800.14. Following the sale, the chief accounting officer now owns 70,455 shares in the company, valued at approximately $3,613,636.95. The disclosure for this sale can be found here. Insiders have sold 18,066 shares of company stock worth $930,280 in the last quarter. Corporate insiders own 5.34% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.com-unik.info/2017/10/12/alkermes-plc-alks-receives-daily-media-impact-rating-of-0-21.html.
Alkermes PLC Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
What are top analysts saying about Alkermes PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Alkermes PLC and related companies.